Top Industry Leaders in the Clinical Genomics Market
Latest Clinical Genomics Companies Update:
Illumina Launched Connected Insights, a cloud-based software for tertiary analysis of clinical next-generation sequencing data, in March 2023.
Natera Received FDA approval for their Signatera™ MRD (minimal residual disease) test for bladder cancer in August 2023.
Myriad Genetics Partnered with the Dana-Farber Cancer Institute in December 2023 to develop and clinically validate new genetic tests for cancer risk assessment.
Invitae Corporation Announced the acquisition of Counsyl, Inc. in January 2024, strengthening their position in carrier screening and genetic testing services.
10x Genomics Developed the Visium Spatial Gene Expression platform for analyzing gene activity patterns within tissue samples, offering valuable insights into disease mechanisms.
List of Clinical Genomics Key companies in the market
-
Quest Diagnostics Incorporated (U.S.)
-
Eurofins Scientific SE (Luxembourg)
-
Illumina, Inc. (U.S.)
-
PerkinElmer, Inc. (U.S.)
-
NeoGenomics Inc. (U.S.)
-
Foundation Medicine, Inc. (U.S.)
-
Rosetta Genomics Ltd. (Israel)
-
Invitae Corporation (U.S.)
-
Myriad Genetics, Inc. (U.S.)
-
Natera, Inc. (U.S.)
-
Genomic Health, Inc. (U.S.)
-
OPKO Health, Inc. (U.S.)
-
Centogene AG (Germany)
-
Clinical Genomics Pty Ltd. (Australia)
-
23andMe, Inc. (U.S.)
-
Iverson Genetic Diagnostics, Inc. (U.S.)
-
Veritas Genetics (U.S.)
-
Gene by Gene, Ltd. (U.S.)
-
GenomeDx Biosciences, Inc. (Canada)
-
MedGenome (India)
-
Strand Life Sciences Pvt. Ltd. (India)
-
Beijing Genomics Institute (BGI) (China)
-
Retrogen, Inc. (U.S.)
-
Personalis, Inc. (U.S.)
-
PathGroup (U.S.)